Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 and DC-CIK for Solid Tumors
NCT03815630Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Whole Cell Cancer Vaccines
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab and dendritic cell vaccine + cytokine-induced killer cells in solid tumor, sponsored by Allife Medical Science and Technology. Primary endpoint: occurrence of treatment related adverse events at 1 year. Status: unknown.
02
Drugs
pembrolizumabdendritic cell vaccine + cytokine-induced killer cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03815630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815630.